Jimeno Research Lab

The Jimeno Lab aims to advance the understanding and treatment of cancer, with a particular emphasis on head and neck squamous cell carcinoma (HNSCC) and salivary gland malignancies, through innovative translational research and therapeutic development. A central focus of the Jimeno Lab is understanding cancer stem cell biology, tumor heterogeneity, and the molecular mechanisms underlying tumor growth, treatment resistance, and disease progression. The Jimeno Lab develops sophisticated patient-derived xenograft (PDX) and humanized mouse models to investigate tumor–microenvironment interactions, immune responses, and therapeutic vulnerabilities in clinically relevant settings. These models are used to identify and evaluate novel targeted therapies, particularly agents directed against critical oncogenic pathways such as PI3K, Wnt, Hedgehog, and BMI1, as well as emerging approaches targeting protein synthesis and translation elongation, including SVC112.

Lab Personnel

Antonio Jimeno, MD, PhD

Principal Investigator

Nathaniel Alzofon, MS

Research Services Professional

Tugy Chimed, MS

Sr. Research Services Professional

Stephen Keysar, PhD

Associate Professor, Research

Phuong Le, PhD

Research Associate

Bettina Miller, MS

Sr. Research Services Professional

J. Jason Morton, PhD

Assistant Professor, Research

Cera Nieto, PhD

Post-Doctoral Fellow

Selected Publications

Keysar SB, Gomes N, Miller B, Jackson BC, Le PN, Morton JJ, Reisinger J, Chimed TS, Gomez KE, Nieto C, Frederick B, Pronk GJ, Somerset HL, Tan AC, Wang XJ, Raben D, Su TT, Jimeno A. Targeting head and neck cancer stem cells by inhibiting translation elongation with SVC112. Cancer Res. 2020 Mar 1;80(5):1183-1198. PMID: 31911553.

Morton JJ, Jackson BC, Keysar SB, Reisinger J, Chimed TS, Le PN, Gomez KE, Nieto C, Miller B, Gao D, Tan AC, Somerset HL Medina T, Wang XJ, Robinson W, Roop D, Gonzalez R, Jimeno A. Studying patient immunotherapy resistance and tumor hyperprogression in an autologous humanized mouse xenograft melanoma model. Molecular Cancer Research. 2020 Oct. PMID: 33087417.

Jimeno A, Moore KN, Gordon M, Chugh R, Diamond JR, Aljumaily R, Mendelson D, Kapoun AM, Xu L, Stagg R, Smith DC. A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. Invest New Drugs. 2018 Sep 19. PMID: 30229512.

Le PN, Keysar SB, Miller B, Eagles JR, Chimed TS, Reisinger J, Gomez KE, Nieto C, Jackson BC, Somerset HL, Morton JJ, Wang XJ, Jimeno A. Wnt signaling dynamics in head and neck squamous cell cancer tumor-stroma interactions. Mol Carcinog. 2019 Mar;58(3):398-410. PMID: 30378175

Gomez K, Wu F, Keysar SB, Morton JJ, Miller B, Chimed TS, Le PN, Nieto C, Chowdhury FN, Tyagi A, LyonsTR, Young CD, Zhou H, Somerset HL, Wang XJ, Jimeno A. Cancer cell CD44 mediates macrophage/monocyte-driven regulation of head and neck cancer stem cells. Cancer Res 2020, CAN-20-1079 accepted 7/29/2020. 10.1158/0008-5472.

CMS Login